Who owns Longeveron Inc. (LGVN)? Elite investor 13F holders
1 tracked elite investors reported holding Longeveron Inc as of 2026-06-30, including Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
1 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome;…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | LONGEVERON INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 13938.00 USD | 19827.000000 | Shares | buy | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.